BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38466231)

  • 21. Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1.
    Lui VW; Boehm AL; Koppikar P; Leeman RJ; Johnson D; Ogagan M; Childs E; Freilino M; Grandis JR
    Mol Pharmacol; 2007 May; 71(5):1435-43. PubMed ID: 17325127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.
    Zeng S; Huang W; Zheng X; Liyan Cheng ; Zhang Z; Wang J; Shen Z
    Eur J Med Chem; 2021 Jan; 210():112981. PubMed ID: 33160761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.
    McCoull W; Cheung T; Anderson E; Barton P; Burgess J; Byth K; Cao Q; Castaldi MP; Chen H; Chiarparin E; Carbajo RJ; Code E; Cowan S; Davey PR; Ferguson AD; Fillery S; Fuller NO; Gao N; Hargreaves D; Howard MR; Hu J; Kawatkar A; Kemmitt PD; Leo E; Molina DM; O'Connell N; Petteruti P; Rasmusson T; Raubo P; Rawlins PB; Ricchiuto P; Robb GR; Schenone M; Waring MJ; Zinda M; Fawell S; Wilson DM
    ACS Chem Biol; 2018 Nov; 13(11):3131-3141. PubMed ID: 30335946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation.
    Gross PH; Sheets KJ; Warren NA; Ghosh S; Varghese RE; Wass KWass KE; Kadimisetty K
    Biochem Biophys Res Commun; 2022 Nov; 628():68-75. PubMed ID: 36084553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.
    He S; Fang Y; Wu M; Zhang P; Gao F; Hu H; Sheng C; Dong G
    J Med Chem; 2023 Dec; 66(24):16828-16842. PubMed ID: 38055861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide.
    Zhang F; Wu Z; Chen P; Zhang J; Wang T; Zhou J; Zhang H
    Bioorg Med Chem; 2020 Jan; 28(1):115228. PubMed ID: 31813613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer.
    Li H; Wang L; Cao F; Yu D; Yang J; Yu X; Dong J; Qin JJ; Guan X
    Front Pharmacol; 2022; 13():944455. PubMed ID: 36034876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemical degrader enhances the treatment of androgen receptor-positive triple-negative breast cancer.
    Wu Y; Xue J; Li J
    Arch Biochem Biophys; 2022 May; 721():109194. PubMed ID: 35337811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
    Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
    Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
    Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
    Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation.
    Bi T; Liang P; Zhou Y; Wang H; Huang R; Sun Q; Shen H; Yang S; Ren W; Liu Z
    J Med Chem; 2023 Nov; 66(21):14843-14852. PubMed ID: 37871321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Advances in the preclinical and clinical research of proteolysis targeting chimera].
    Liu Z; Liu S
    Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3615-3627. PubMed ID: 37805842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach.
    Chen Q; Liu C; Wang W; Meng X; Cheng X; Li X; Cai L; Luo L; He X; Qu H; Luo J; Wei H; Gao S; Liu G; Wan J; Israel DI; Li J; Dou D
    ACS Chem Biol; 2023 Jan; 18(1):25-33. PubMed ID: 36606710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo.
    Wei M; Zhao R; Cao Y; Wei Y; Li M; Dong Z; Liu Y; Ruan H; Li Y; Cao S; Tang Z; Zhou Y; Song W; Wang Y; Wang J; Yang G; Yang C
    Eur J Med Chem; 2021 Jan; 209():112903. PubMed ID: 33256948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.
    Sattu K; Hochgräfe F; Wu J; Umapathy G; Schönherr C; Ruuth K; Chand D; Witek B; Fuchs J; Li PK; Hugosson F; Daly RJ; Palmer RH; Hallberg B
    FEBS J; 2013 Nov; 280(21):5269-82. PubMed ID: 23889739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific MHC-I Peptides Are Induced Using PROTACs.
    Jensen SM; Potts GK; Ready DB; Patterson MJ
    Front Immunol; 2018; 9():2697. PubMed ID: 30524438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass.
    Walker EC; Johnson RW; Hu Y; Brennan HJ; Poulton IJ; Zhang JG; Jenkins BJ; Smyth GK; Nicola NA; Sims NA
    J Biol Chem; 2016 Oct; 291(41):21703-21716. PubMed ID: 27539849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. De Novo Design of an Androgen Receptor DNA Binding Domain-Targeted peptide PROTAC for Prostate Cancer Therapy.
    Ma B; Fan Y; Zhang D; Wei Y; Jian Y; Liu D; Wang Z; Gao Y; Ma J; Chen Y; Xu S; Li L
    Adv Sci (Weinh); 2022 Oct; 9(28):e2201859. PubMed ID: 35971165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.
    Maneiro MA; Forte N; Shchepinova MM; Kounde CS; Chudasama V; Baker JR; Tate EW
    ACS Chem Biol; 2020 Jun; 15(6):1306-1312. PubMed ID: 32338867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bivalent Ligands for Protein Degradation in Drug Discovery.
    Scheepstra M; Hekking KFW; van Hijfte L; Folmer RHA
    Comput Struct Biotechnol J; 2019; 17():160-176. PubMed ID: 30788082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.